Fact-checked by Grok 2 weeks ago

bioRxiv

bioRxiv is a free online archive and distribution service for unpublished preprints in the life sciences, allowing researchers to share their findings immediately with the global before undergoing formal . Operated as part of the non-profit openRxiv , it covers all areas of and related fields, with submissions undergoing a screening process for offensive or off-topic content rather than editorial or scientific review. Authors retain full copyright of their work, which is typically distributed under licenses to facilitate broad reuse and access. Launched in November 2013 by (CSHL), a leading and educational institution, bioRxiv was co-founded by John Inglis and Richard Sever to establish preprints as a journal-independent for disseminating life science results. Initially managed directly by CSHL, it has since been integrated into the openRxiv framework, which also oversees the server for health sciences preprints, reflecting a commitment to principles. The platform's mission emphasizes rapid, equitable sharing of scientific advances, free from traditional publishing delays, and it has grown significantly, hosting over 300,000 preprints with approximately 4,500 new submissions each month as of October 2025. bioRxiv has profoundly influenced biomedical publishing by accelerating the pace of discovery and enabling real-time collaboration among scientists worldwide. Its role became particularly prominent during the (2019–2022), where it facilitated the swift dissemination of thousands of studies on the virus, , and related responses, often preceding journal publications by weeks or months. Governed by a Scientific Advisory Board chaired by co-founder John Inglis and comprising experts from diverse institutions, bioRxiv continues to evolve, incorporating features like funder integration and preprint review widgets to enhance transparency and context. By prioritizing accessibility— with no fees for authors or readers—and participation, it has become a cornerstone of modern biological research communication.

Overview

Purpose and Scope

bioRxiv is an open-access preprint repository designed to facilitate the rapid dissemination of research in the biological sciences prior to peer review. It serves as a free online archive where researchers can upload complete but unpublished manuscripts, enabling the sharing of preliminary findings to accelerate scientific progress. The primary purpose of bioRxiv is to allow authors to establish priority of discovery, solicit early feedback from the community, and foster collaboration among scientists in the life sciences. By providing a platform for quick publication without the delays of traditional journal review, it promotes transparency and iterative improvement in research outputs. This model supports the non-peer-reviewed nature of preprints while emphasizing their role in building upon existing knowledge. The scope of bioRxiv encompasses all disciplines within the life sciences, including , , , , and interdisciplinary areas such as bioinformatics and . It operates on a non-commercial basis, offering free access to deposited content for readers worldwide and no submission fees for authors, with sustainability supported by institutional funding. Preprints on bioRxiv are assigned digital object identifiers (DOIs), making them permanently citable and discoverable in academic databases. In comparison to broader preprint servers like , which covers , , and quantitative among other fields, bioRxiv provides a specialized focus on the life sciences with tailored moderation and categorization for biological research. This biology-centric approach ensures and for life scientists, while the integration enhances its utility in scholarly workflows.

Founding and Governance

bioRxiv was established in November 2013 by (CSHL) to address the growing demand among biologists for a dedicated platform to rapidly share s, fostering greater collaboration and openness in the life sciences. This initiative responded to the limitations of existing preprint servers, which were primarily focused on physics and lacked biology-specific moderation and categorization, thereby filling a critical gap for researchers in the biological sciences. The platform was co-founded by John Inglis, then executive editor of CSHL Press, and Richard Sever, head of Press, who recognized the need for a biology-oriented amid increasing calls from the for faster dissemination of unpublished findings. Initial funding came directly from CSHL, supplemented by contributions from the broader , enabling the development of the server without subscription fees for authors or readers. As a non-profit service, bioRxiv was originally operated under the auspices of CSHL, with governance provided by an editorial team and an composed of prominent biologists to guide policies on , , and expansion. In March 2025, bioRxiv transitioned to management by openRxiv, an independent non-profit organization designed to ensure long-term stability through diversified governance, including a Scientific and Medical chaired by co-founder John Inglis and comprising experts such as , Fiona Watt, and Leslie Vosshall, who steer strategic decisions on operations and policy. In August 2025, openRxiv appointed Dr. Tracy Teal as its first CEO to lead the organization. Funding for bioRxiv has evolved from early reliance on CSHL's internal resources and philanthropic support to a more robust model emphasizing grants and institutional partnerships. Key early backing included a significant grant from the in 2017 to cover staff, technology, and infrastructure, while current sustainability is maintained through donations from foundations like the Family Foundation and contributions from subscribing institutions such as , Stanford, and the .

History

Launch and Early Years

bioRxiv was officially launched in November 2013 by as a testing phase, enabling researchers to post in various categories without . The platform aimed to accelerate the dissemination of biological research by allowing immediate sharing of results, drawing inspiration from the physics preprint server , with the first submissions focusing on core life sciences topics. In its early years, bioRxiv encountered resistance from parts of the community, primarily due to concerns over the unvetted nature of preprints potentially leading to and implications for researchers' careers, such as scooping or hiring biases. Initial submission volumes were low, with only around 800 preprints posted in the first year ending November 2014, reflecting hesitation among biologists accustomed to traditional validation before public sharing. To address these hurdles, bioRxiv implemented key initiatives, including the integration of identifiers in 2015 to enhance author identification and traceability. Promotion efforts involved partnerships with scientific societies, such as the Society of , which in November 2014 launched a portal allowing simultaneous submissions to its journals Genetics and G3: Genes|Genomes|Genetics via bioRxiv, easing adoption. These steps, combined with policy shifts from major journals like and permitting postings prior to submission, helped drive growth from dozens of monthly submissions in 2013 to thousands annually by 2015, with over 3,900 preprints posted by the end of that year.

Expansion and Key Milestones

Following its initial launch, bioRxiv experienced steady growth from to , with monthly submissions increasing from around 300 to over 800 preprints, driven by expanding adoption in fields like and . This period marked a shift toward broader acceptance of preprints in the life sciences, as evidenced by rising download rates exceeding 1 million per month by late . In June 2019, bioRxiv expanded its ecosystem with the launch of , a sister server dedicated to health sciences preprints, developed in partnership with , , and to address clinical and epidemiological research needs previously restricted on bioRxiv. By the end of 2019, bioRxiv had surpassed 94,000 total preprints, reflecting its maturation as a central repository for unpublished biological research. The catalyzed a dramatic surge in bioRxiv submissions during 2020, with over 10,000 biology-related preprints posted amid the global health crisis, including approximately 8,400 dedicated to and related topics. This influx, representing a more than twofold increase in monthly postings compared to pre-pandemic levels, enabled rapid dissemination of findings on viral transmission, development, and therapeutic interventions, playing a pivotal role in the international scientific response by allowing researchers to share results weeks or months ahead of traditional . The heightened visibility of preprints during this period underscored bioRxiv's utility in crisis-driven research acceleration. As of 2025, bioRxiv has achieved significant recent milestones, including the integration of tools for preprint screening and summarization to enhance and user accessibility, such as automated synopses tailored to different reading levels introduced in a 2023 pilot. In March 2025, bioRxiv and transitioned to management under the newly formed non-profit openRxiv organization, enhancing their independence and commitment to . As of October 2025, the platform hosts over 418,000 s cumulatively, demonstrating sustained growth and widespread reliance by the . Additionally, bioRxiv has forged partnerships with agencies, including from the and alignment with policies like the 2022 OSTP memo encouraging immediate , which has influenced mandatory requirements for grant-funded work at organizations such as the NIH. These collaborations facilitate funder metadata integration during submissions, improving traceability and compliance with mandates. Policy evolutions have further strengthened bioRxiv's framework, with the introduction of formalized version tracking in 2019 to maintain archival access to all revisions and updated guidelines on withdrawals and notices of errors or misconduct, with further clarifications in 2023. These changes, informed by analyses of preprint revisions and retractions during the , promote transparency while preserving the platform's non-peer-reviewed nature.

Operations

Submission Process

Authors submit manuscripts to bioRxiv through an online portal at submit.biorxiv.org, requiring registration with an email address and optional ORCID integration for author identification. The workflow involves uploading the manuscript, with the simplest method being a single PDF file containing the full text, figures, tables, and references; alternatively, a Microsoft Word file can be uploaded along with separate figure files, which are converted to PDF. LaTeX or TeX source files must be converted to PDF prior to submission. Authors then enter required metadata, including the title, author list with affiliations, abstract, keywords, and selection of one or more subject categories from bioRxiv's life sciences classification system to ensure appropriate indexing. Submissions must consist of original, unpublished research in the biological sciences; prior publication in any form, including peer-reviewed journals, disqualifies the manuscript, and authors grant a non-exclusive license to bioRxiv and choose from several Creative Commons distribution options, such as CC BY, to permit reuse with varying conditions including attribution. In January 2025, the license selector was updated to promote CC BY as the default option. Upon completion, the system automatically assigns a unique Digital Object Identifier (DOI) in the format doi:10.1101/XXXXXXX once the preprint passes initial screening. Following submission, undergo a basic screening for compliance and scientific appropriateness, typically within 48 hours, after which they are posted publicly and immediately accessible worldwide. Authors may update their at any time before journal acceptance by submitting a revised version through the portal, resulting in a new version number (e.g., v2) linked to the original while preserving all prior versions. Withdrawals are allowed via the submission system prior to formal publication, with the withdrawn remaining online but marked as withdrawn to maintain transparency. BioRxiv supports technical features such as export of and references in XML or formats for integration with reference managers like or , and each includes tracking to display real-time metrics on views, downloads, shares, and citations from external sources.

Moderation and Policies

bioRxiv employs a non-editorial screening process to ensure submissions align with its scope and ethical standards, conducted by in-house staff and volunteer affiliates. This multi-step review checks for completeness of submission details, relevance to biological or biomedical research, via automated text analysis, and potential ethical violations such as overt information or material that could pose risks. The process typically takes 24–48 hours, though it may extend over weekends or holidays, with approximately 5% of submissions declined for failing these criteria. Unlike traditional journals, there is no post-publication moderation beyond handling reported concerns, emphasizing rapid dissemination while maintaining basic integrity. Key policies govern content to uphold scientific and ethical norms. Papers reporting results of clinical trials must be submitted to , which requires registration of the trial in a public database to ensure oversight and and mitigate risks associated with unvetted interventions. Guidelines encourage and measures to enhance , such as depositing datasets in public repositories, though these are not mandatory to avoid barriers to preprinting. As of September 2025, bioRxiv offers integration with for direct data submission alongside the preprint. For corrections and retractions, authors may request updates to address errors, while reported issues trigger staff review; confirmed violations like or unethical conduct can lead to removal of the preprint. Enforcement relies on a combination of automated tools, staff oversight, and involvement. A reporting system allows users to flag concerns about posted preprints via an online form, prompting that may result in revisions, retractions, or bans on future submissions by offending authors. bioRxiv adheres to the guidelines of the (COPE) for handling disputes, ensuring consistent application of ethical standards in cases of alleged misconduct. Policies evolve to address emerging challenges in practices. In response to the rise of generative tools, bioRxiv updated its guidelines to require authors to take full for AI-generated content, including validation of its accuracy, and to disclose such use where it contributes substantially to the , aligning with broader efforts to maintain authorship integrity. Additionally, submissions are screened for dual-use of concern—studies with potential for misuse in harmful applications, such as bioweapons—potentially leading to rejection if they challenge public health consensus without sufficient safeguards. These measures reflect bioRxiv's commitment to balancing with responsible dissemination.

Content and Disciplines

Covered Fields

bioRxiv covers more than 25 subject categories spanning the life sciences, enabling researchers to assign preprints to specific disciplines for better organization and discovery. Primary categories include biochemistry, , , , bioinformatics, cancer biology, , , , , , , , , plant biology, and , among others such as animal behavior and , bioengineering, , , , and , , and . These categories facilitate targeted feeds and searches, with subcategories like emerging as specialized areas within broader molecular and engineering domains. The platform's scope extends interdisciplinarily, incorporating overlaps with physics through and with via and bioinformatics, allowing integration of quantitative methods into biological . However, bioRxiv strictly excludes submissions offering purely medical advice or containing patient-specific information, emphasizing its role as a for scientific preprints rather than clinical guidance. Following a pilot, the Clinical Trials and categories are now closed to new submissions, though revisions to existing papers are accepted. Since its launch in 2013, bioRxiv's covered fields have evolved from an initial emphasis on molecular biology, genetics, genomics, evolutionary biology, and computational biology—fields that dominated early submissions—to a broader inclusion of quantitative biology areas by 2017, such as enhanced categories in and . This expansion reflects the growing prevalence of interdisciplinary work in the life sciences, with additional categories like animal behavior and cognition and cancer biology becoming established to accommodate diverse research trends. In terms of usage, submissions vary by category, with comprising about 18% of preprints in 2025, about 9%, and bioinformatics approximately 8%; , a key area, accounts for roughly 4% of total submissions as of that year. These proportions highlight the platform's emphasis on and computational approaches while maintaining balance across experimental and quantitative disciplines.

Content Types and Formats

bioRxiv primarily hosts preprints in the form of full articles, which report original experimental or theoretical work in the biological sciences. These include methods papers that describe novel techniques or protocols applicable to multiple studies, as well as replication studies aimed at verifying prior findings to enhance . The platform explicitly excludes review articles, opinion pieces, and other non-original content, focusing instead on unpublished manuscripts that advance primary . Manuscripts on bioRxiv are displayed in PDF format, which serves as the standard for public viewing and includes the full text, figures, and tables in a single compiled file. Authors may optionally upload source files, such as or documents, to facilitate revisions or accessibility for readers interested in editable versions. Supplemental materials, including datasets, code, and additional files, are supported through hyperlinks to external repositories like , allowing integration without embedding large files directly on the platform. Key features of bioRxiv preprints include embeddable high-resolution figures that can be extracted and reused in presentations or other publications, as well as hyperlinks to external resources such as repositories or related works for seamless . Each preprint receives a upon posting, in the form of a with the submission date, establishing priority for scientific claims and enabling chronological tracking of ideas. Limitations on content ensure focus on textual manuscripts: bioRxiv does not accept submissions consisting solely of multimedia, such as videos or interactive elements without accompanying text, emphasizing self-contained written documents. File sizes are constrained, with main PDF uploads typically limited to around 50 MB and supplemental files (e.g., movies) capped at 40 MB to maintain efficient processing and storage.

Relationship with Publishing

Preprints and Traditional Journals

One key advantage of posting on bioRxiv is that it establishes scientific by timestamping findings with a , allowing immediate dissemination without delaying submission to traditional journals. This enables authors to receive community feedback while pursuing peer-reviewed , accelerating the cycle. Many prominent journals, such as journals and , explicitly accept or encourage postings, viewing them as complementary to formal review processes rather than prior . bioRxiv operates under a non-exclusive posting policy, meaning authors retain full rights to submit their work to peer-reviewed journals after upload, with no restrictions on subsequent publication. This aligns with widespread journal policies permitting use, and published versions often acknowledge the original bioRxiv posting in footnotes or methods sections to credit the initial disclosure. Such transparency helps maintain the integrity of the scientific record while bridging and journal ecosystems. High-profile examples illustrate this seamless transition, such as the 2020 bioRxiv preprint on 2, which detailed breakthroughs in and garnered widespread attention before its 2021 publication in , influencing subsequent AI-driven biology research. Similarly, early applications of CRISPR-Cas9 technologies, including off-target effect analyses and editing optimizations, have appeared as bioRxiv preprints prior to journal acceptance, enabling rapid iteration on gene-editing tools amid evolving discoveries. These cases highlight how preprints foster priority claims and collaborative refinement leading to validated publications. Studies from 2019 indicate approximately 70% of bioRxiv preprints result in peer-reviewed versions within 1-2 years, underscoring the platform's role in facilitating eventual formal publication across diverse outlets. This high conversion rate reflects bioRxiv's integration into standard workflows, where preprints serve as a foundational step rather than an endpoint. Recent tools, such as the October 2025 PreprintToPaper dataset, further enhance this by systematically linking preprints to their published counterparts, enabling large-scale analysis of outcomes.

Open Peer Review Integration

bioRxiv integrates with external platforms to facilitate open and portable , enabling authors to receive transparent feedback on preprints that can be transferred to participating journals without restarting the review process. A key collaboration is with Review Commons, launched in December 2019 by EMBO in partnership with ASAPbio, which provides journal-agnostic for life sciences preprints. Under this system, authors submit preprints to Review Commons for review, and the resulting reports—along with author responses—are made available as "refereed preprints" that can be ported to over 20 affiliate journals, including those from EMBO Press, streamlining publication workflows. This integration enhances bioRxiv's role by automatically posting these transparent reviews alongside the preprint on the platform when authors opt to transfer their manuscript. In late 2019, bioRxiv initiated a pilot for optional , allowing authors to request public posting of peer reviews from select journals and services directly next to their preprints. This built on partnerships with ASAPbio to experiment with community-driven review models, including efforts to make reviews portable and visible early in the publication cycle. Authors must opt in to the public posting, committing to share all reviews (positive or negative) if approved, and they may include revisions or rebuttals. Feedback is typically signed and non-anonymous if reviewers choose, though anonymity remains the default option to encourage candid input. These reviews integrate seamlessly with journal workflows, such as those at EMBO Press, where affiliate editors use the existing reports to expedite decisions, often without additional reviewing. The initiatives have improved review efficiency by reducing redundant evaluations and accelerating timelines. In Review Commons' first nine months through 2020, 98% of rejected manuscripts and 86% of accepted ones bypassed further at affiliates, with journals issuing decisions in as little as 8 days. Approximately 30% of reviewed manuscripts during this period were posted as refereed preprints on bioRxiv, demonstrating early adoption of this transparent model. By promoting signed, public feedback, these integrations foster greater accountability and in the peer review process.

Impact and Reception

Adoption and Usage Statistics

Since its launch in , bioRxiv has experienced substantial growth in submissions, starting with approximately 200 preprints that year and reaching over 60,000 annually by 2025. Monthly new submissions averaged around 5,000 in 2024 and over 5,500 in 2025, contributing to a cumulative total exceeding 418,000 preprints as of 2025. This expansion peaked during the 2020-2022 , when submissions surged due to the urgency for rapid dissemination of research findings, with monthly volumes exceeding 3,000 in late 2020 alone. The platform's user base consists primarily of academic researchers, including principal investigators, postdoctoral scholars, and graduate students in the life sciences. Geographically, about 60% of authors hail from and , though participation from , , and other regions has increased steadily since 2014, reflecting a mean of 1.6 countries per and rising international collaboration. BioRxiv preprints achieve citation rates comparable to or exceeding those of traditional journal articles, with deposited papers receiving substantially more citations—around 50–60% higher in pre-2020 studies. further highlight their influence, showing elevated social media engagement and online mentions compared to non-preprint publications, which underscores their role in accelerating scientific discourse. In terms of accessibility, bioRxiv records over 5 million PDF downloads monthly as of 2024, facilitating widespread dissemination among global researchers. Preprints are indexed by Google Scholar, enabling seamless integration into academic search and citation tracking systems.

Criticisms and Challenges

One major concern with bioRxiv is the potential for disseminating misinformation through unvetted preprints, as these manuscripts bypass traditional peer review and can enter public discourse rapidly. During the COVID-19 pandemic, a surge in preprints on preprint servers like bioRxiv contributed to the spread of unverified claims, exacerbating disinformation and complicating public health responses. For instance, analyses highlighted how non-peer-reviewed papers fueled misleading narratives on virus transmission and treatments, underscoring the risks when preliminary findings are amplified by media or social platforms without scrutiny. Another persistent issue is the fear of "scooping," where researchers hesitate to post preprints on bioRxiv due to concerns that competitors might appropriate their ideas before formal publication. Surveys of life scientists reveal that this apprehension deters a subset of authors, particularly in competitive fields, from using preprint servers despite benefits like faster dissemination. Evidence suggests actual instances of scooping remain rare, yet the perception alone influences submission rates and perpetuates inequities in early sharing. Equity challenges also arise for non-English-speaking researchers, who face linguistic barriers on English-centric platforms like bioRxiv, limiting their participation and visibility. Non-native speakers often invest disproportionate effort in preparation, which can disadvantage contributions from global south institutions and hinder diverse perspectives in . Proposals advocate for integrated support, such as peer proofing and tools within systems, to foster inclusion. Specific debates have highlighted risks akin to , with early criticisms around 2017 questioning the quality control of unmoderated preprints and their potential to mimic low-oversight outlets. Additionally, moderating dual-use research of concern, such as gain-of-function studies in , poses ongoing challenges; bioRxiv's policies exclude content that could enable misuse or harm , but the rapid influx of pandemic-related submissions strained screening for risks. In response, bioRxiv has implemented enhanced screening protocols, including checks for , offensive material, and dual-use implications, while increasing about rejection criteria to build trust. Education campaigns, supported by organizations like ASAPbio, emphasize responsible use and the value of community feedback over formal review. Studies comparing quality to peer-reviewed articles indicate low error rates in bioRxiv submissions, with only minor differences in reporting standards (e.g., 5% absolute improvement post-review), suggesting preprints are generally reliable for early sharing. Looking ahead to , scalability remains a challenge amid AI proliferation, as generative tools could flood servers with fabricated or low-effort content, complicating detection of authentic research and amplifying dual-use risks in . There are also calls for stronger integration with non-Western research communities, addressing underrepresentation from low- and middle-income countries where resource constraints limit preprint-to-journal transitions and cultural biases persist in global science norms.

References

  1. [1]
    Frequently Asked Questions (FAQ) - bioRxiv
    bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution.
  2. [2]
    Submission Guide - bioRxiv
    bioRxiv is an online archive and distribution service for preprints in the life sciences. bioRxiv is operated by openRxiv, a non-profit organization ...
  3. [3]
    About - openRxiv
    openRxiv is the organizational home of bioRxiv and medRxiv, platforms for sharing biomedical research manuscripts before journal peer review.
  4. [4]
    BioRxiv: A Progress Report - ASAPbio
    Feb 12, 2016 · bioRxiv (biorxiv.org) is a not-for-profit, online archiving and distribution service for preprints[1] of research papers in the life sciences.
  5. [5]
    Adding funder information to bioRxiv preprints
    Sep 4, 2025 · During submission, bioRxiv authors can select their funder(s) from the standardized list of research organizations available in a drop-down menu ...
  6. [6]
    A new bioRxiv dashboard widget
    Jan 17, 2025 · The dashboard is now accessible alongside every article by clicking on a new widget (“Reviews and Context”) to the right of the abstract.
  7. [7]
    About bioRxiv
    bioRxiv (pronounced "bio-archive") is a free online archive and distribution service for unpublished preprints in the life sciences.
  8. [8]
    CSHL launches bioRxiv, a freely accessible, citable preprint server ...
    Nov 12, 2013 · “We have established BioRxiv in response to an evident desire among many scientists for more collaboration and openness in their work, with the ...
  9. [9]
    The natural evolution of bioRxiv and medRxiv
    Mar 11, 2025 · The free online platforms bioRxiv and medRxiv, developed at Cold Spring Harbor Laboratory, will now operate under openRxiv's research community ...
  10. [10]
    BioRxiv preprint server gets cash boost from Chan Zuckerberg ...
    terms of which have not been disclosed — will pay for staff, technology development and other infrastructure at ...
  11. [11]
    BioRxiv at 1 year: A promising start - Science
    Nov 11, 2014 · BioRxiv's creators wanted to persuade biologists to follow the lead of most physicists and share their raw manuscripts on a free online archive ...
  12. [12]
    What bioRxiv's first 30,000 preprints reveal about biologists - Nature
    Jan 22, 2019 · More than 1 million studies are now downloaded from the site every month, mostly in neuroscience, bioinformatics and genomics.
  13. [13]
    Chan Zuckerberg Initiative Awards $2 Million to medRxiv
    medRxiv was launched in June 2019 as a partnership between Cold Spring Harbor Laboratory (CSHL), Yale University, and global health knowledge provider BMJ. The ...
  14. [14]
    bioRxiv: Trends and analysis of five years of preprints
    Nov 2, 2019 · Overall, more than 37,000 preprints from bioRxiv were analysed for this paper, and more than 1,200 published, peer reviewed articles with ...
  15. [15]
    COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
    COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv. 31,050 Articles (22,627 medRxiv, 8,423 bioRxiv). Most recent first Page 1: Articles 1- ...
  16. [16]
    Preprinting the COVID-19 pandemic | bioRxiv
    Feb 5, 2021 · Over 30,000 COVID-19 preprints were released on preprint servers, with increased access, faster review, and shorter preprints.
  17. [17]
    The evolving role of preprints in the dissemination of COVID-19 ...
    An analysis of bioRxiv and medRxiv during the first 10 months of the COVID-19 pandemic reveals that the pandemic has resulted in a cultural shift in the use of ...
  18. [18]
    AI writes summaries of preprints in bioRxiv trial - Nature
    Nov 14, 2023 · Large language model creates synopses of papers aimed at various reading levels to help scientists sift through the literature.
  19. [19]
    bioRxiv Monthly Content Summary
    bioRxiv Monthly Content Summary ; Mar, 2025, 4,083, 274,331 ; Apr, 2025, 3,841, 278,172 ; May, 2025, 4,331, 282,503 ; Jun, 2025, 3,948, 286,451 ...Missing: preprints | Show results with:preprints
  20. [20]
    bioRxiv and medRxiv response to the OSTP memo - an open letter ...
    Apr 11, 2023 · A preprint mandate would achieve universal access for both authors and readers upstream, ensuring the focus remains on providing access to ...
  21. [21]
    bioRxiv Manuscript Processing System
    Enter the Author Area to: Submit a New/Revised Manuscript; Continue a Manuscript Submission; Proof a converted manuscript. Enter the Personal Info ...
  22. [22]
    Screening Procedures on bioRxiv
    Jun 13, 2022 · Manuscripts submitted to bioRxiv undergo two screening steps. First, in-house screening staff with scientific and editorial expertise check that the details ...
  23. [23]
    bioRxiv Category Summary by Year
    bioRxiv Category Summary by Year ; Physiology · Plant Biology · Scientific Communication And Education ; 24 · 106 · 35 ; 0.51 · 2.26 · 0.75.
  24. [24]
    Subject Collection(s) - bioRxiv
    * The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot ...Subject Collection(s)Biochemistry
  25. [25]
    Category Summary by Year - bioRxiv API
    2013 Category Shares. Category, Articles, Share (%). Biochemistry, 1, 0.92. Bioengineering, 1, 0.92. Bioinformatics, 14, 12.84. Biophysics, 4, 3.67.
  26. [26]
    The evolution, benefits, and challenges of preprints and their ...
    Feb 20, 2022 · It is notable that most journals now accept submissions that have been posted as preprints. The benefits of preprints include fast circulation, ...
  27. [27]
    eLife Latest: What we have learned about preprints
    Jul 1, 2021 · Preprints allow rapid dissemination of findings, are often cited, and eLife now peer reviews them, combining openness with peer review.
  28. [28]
    Motivations, concerns and selection biases when posting preprints
    In terms of benefits of posting a preprint to bioRxiv, by far the most-frequently agreed with reason was that they “Increased awareness of your research” (73%) ...
  29. [29]
    CRISPR | bioRxiv
    Optimizing CRISPR/Cas9 mutagenesis in Drosophila da neurons to avoid cytotoxicity · Advanced pipeline for CRISPR/Cas9 off-targets detection in Guide-seq and ...
  30. [30]
    Review Commons—pre‐journal peer review | EMBO reports
    Dec 2, 2019 · Review Commons is a new platform initiated by EMBO in collaboration with ASAPbio, which offers scientists high‐quality peer review before journal submission.Missing: uptake | Show results with:uptake
  31. [31]
    Evaluating Review Commons – The First 9 Months - ASAPbio
    Sep 29, 2020 · Over the evaluation period, it took Review Commons a median of 37 days to return peer reviews to authors whose manuscripts were sent for peer ...Missing: uptake | Show results with:uptake
  32. [32]
    In bid to boost transparency, bioRxiv begins posting peer reviews ...
    Oct 10, 2019 · BioRxiv, the server for life sciences preprints, has begun an experiment that allows select journals and independent peer-review services to publicly post ...
  33. [33]
    Convening The Review Commons Community - ASAPbio
    Feb 6, 2020 · Efforts are underway to make Review Commons more interoperable and portable for potential integration with other peer review projects.
  34. [34]
    Guidelines for Reviewers - Review Commons
    Review Commons makes the peer review process public (by default without referee names) to provide an informative resource to researchers interested in the ...Missing: opt- bioRxiv
  35. [35]
    Guidelines for Authors - Review Commons
    Review Commons will post the reviews and the authors' response on bioRxiv or medRxiv when the authors transfer their manuscript to the first affiliate journal.Missing: integration | Show results with:integration
  36. [36]
    Meta-Research: Tracking the popularity and outcomes of all bioRxiv ...
    Apr 24, 2019 · Data are reported for the monthly number of uploads to and downloads from bioRxiv, and for the number of preprints that are later published ...
  37. [37]
    International authorship and collaboration across bioRxiv preprints
    Jul 27, 2020 · An analysis of 67885 preprints on bioRxiv finds evidence for disparities in international participation that are similar to the disparities ...
  38. [38]
    The relationship between bioRxiv preprints, citations and altmetrics
    Jun 1, 2020 · We found that bioRxiv-deposited journal articles had sizably higher citation and altmetric counts compared to nondeposited articles.2. Methods · 2.1. Preprint And Article... · 2.6. Regression Analysis<|control11|><|separator|>
  39. [39]
    Monthly Usage - bioRxiv Reporting
    bioRxiv Monthly Usage ; Jun, 2023, 6,168,516, 1,411,915 ; Jul, 2023, 6,164,740, 1,467,876 ; Aug, 2023, 6,579,158, 1,593,494 ; Sep, 2023, 7,311,344, 1,285,778 ...
  40. [40]
    The preprint problem: Unvetted science is fueling COVID-19 ...
    May 6, 2020 · Unvetted science is fueling COVID-19 misinformation. Peer review moves to Twitter, muddling public health information.
  41. [41]
    How scientists' rush to publish Covid-19 research fuels disinformation
    May 12, 2020 · A flood of unvetted papers posted to preprint servers highlights the dangers of open-access science in a pandemic.
  42. [42]
    Stark Decline in Journalists' Use of Preprints Postpandemic - PMC
    Abstract. The COVID-19 pandemic accelerated the use of preprints, aiding rapid research dissemination but also facilitating the spread of misinformation.
  43. [43]
    Motivations, concerns and selection biases when posting preprints
    Sep 7, 2021 · Recent studies have found that journal articles that were previously posted to bioRxiv received a higher number of citations or mentions/shares ...
  44. [44]
    A guide to preprinting for early-career researchers - PMC - NIH
    Jul 25, 2022 · We have constructed a guide for ECRs who are considering preprinting to enable them to take ownership over the process and to raise awareness about preprinting ...
  45. [45]
    New policies on preprints and extended scooping protection - EMBO
    Jul 1, 2021 · “The main concern of authors who are hesitant to adopt preprints is the fear of being scooped,” she says. ASAPbio's Executive Director, Jessica ...
  46. [46]
    The manifold costs of being a non-native English speaker in science
    The use of English as the common language of science represents a major impediment to maximising the contribution of non-native English speakers to science.
  47. [47]
    A solution for breaking the language barrier - ScienceDirect.com
    Here, we propose integrating peer language proofing and translation systems in preprint platforms as a solution for promoting equity, diversity, and inclusion ...
  48. [48]
    Rapid Proliferation of Pandemic Research: Implications for Dual ...
    Oct 19, 2021 · For instance, gain-of-function studies and reverse genetics protocols may facilitate the engineering of concerning SARS-CoV-2 variants and other ...
  49. [49]
    Comparing quality of reporting between preprints and peer ...
    Dec 1, 2020 · Peer-reviewed articles had, on average, higher quality of reporting than preprints, although the difference was small, with absolute differences of 5.0%.
  50. [50]
    Limiting open science? Three approaches to bottom-up governance ...
    Oct 4, 2023 · Dual-use research of concern (DURC) refers to research that is intended to provide a clear benefit but whose misapplication could negatively ...
  51. [51]
    Dual-use capabilities of concern of biological AI models
    Here we describe how previous experience and study by scientists and policy professionals of dual-use research in the life sciences can inform dual-use ...<|separator|>
  52. [52]
    Preprints become papers less often when the authors are from lower ...
    Jul 3, 2023 · Analysing the almost 140,000 papers posted on the preprint servers bioRxiv and medRxiv since their inception (in 2013 and 2019, respectively) ...Missing: statistics | Show results with:statistics